Clinical Trials
88
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (84 trials with phase data)β’ Click on a phase to view related trials
Impact of Acthar on Everyday Life of Participants With Severe Keratitis
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 36
- Registration Number
- NCT04169061
- Locations
- πΊπΈ
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
πΊπΈGlobal Research Management, Inc., Glendale, California, United States
πΊπΈEye Research Foundation, Newport Beach, California, United States
MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
- Conditions
- Hepatic Encephalopathy
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Mallinckrodt
- Registration Number
- NCT04128462
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
- Conditions
- Hepatic CirrhosisHepatic Encephalopathy (HE)
- Interventions
- Drug: MNK6106
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 50
- Registration Number
- NCT03712280
- Locations
- πΊπΈ
Southern California Research Center, Coronado, California, United States
πΊπΈInland Empire Clinical Trials, Rialto, California, United States
πΊπΈGlobal Clinical Professionals, Saint Petersburg, Florida, United States
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
- Conditions
- PanuveitisUveitis, PosteriorUveitis, Intermediate
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 5
- Registration Number
- NCT03656692
- Locations
- πΊπΈ
Blue Ocean Clinical Research, Clearwater, Florida, United States
πΊπΈMidwest Eye Institute, Indianapolis, Indiana, United States
πΊπΈMassachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States
Acthar Gel in Participants With Pulmonary Sarcoidosis
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 55
- Registration Number
- NCT03320070
- Locations
- πΊπΈ
UAB Lung Health Center, Birmingham, Alabama, United States
πΊπΈDavid Geffen School of Medicine, Los Angeles, California, United States
πΊπΈNational Jewish Health, Denver, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 18
- Next
News
Mallinckrodt to Present Five Clinical Studies on TERLIVAZ for Hepatorenal Syndrome at DDW 2025
Mallinckrodt will present five clinical analyses of TERLIVAZ (terlipressin) for hepatorenal syndrome with rapid reduction in kidney function (HRS-AKI) at Digestive Disease Week 2025 in San Diego.
Mallinckrodt and Endo to Merge in $6.7B Deal, Creating Pharmaceutical Powerhouse
Mallinckrodt plc and Endo Inc. have agreed to merge in a $6.7 billion transaction, with Endo shareholders receiving $80 million in cash and owning 49.9% of the combined entity.
DEA Approves Increased Production of Vyvanse Amid ADHD Drug Shortages
The DEA has approved Takeda Pharmaceuticals to increase production of Vyvanse by 24% to address ongoing shortages of ADHD medications.
FDA Rejects Mallinckrodt's Abuse-Deterrent Roxicodone Reformulation
The FDA issued a Complete Response Letter for SpecGx LLC's abuse-deterrent, immediate-release reformulation of Roxicodone (oxycodone hydrochloride) tablets.